Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial

Rimei Nishimura, Tomoko Nakagami, Hirohito Sone, Yasuo Ohashi, and Naoko Tajima

Abstract

Background: Although the ADA/EASD/IDF International Expert Committee recommends using hemoglobin A1c (HbA1c) to define diabetes, the relation between HbA1c and cardiovascular disease (CVD) has not been thoroughly investigated. We analyzed this relation using clinical data on Japanese individuals with hypercholesterolemia.

Methods: In the large-scale MEGA Study 7832 patients aged 40 to 70 years old with mild-to-moderate hypercholesterolemia without CVD were randomized to diet alone or diet plus pravastatin and followed for >5 years. In the present subanalysis of that study a total of 4002 patients with baseline and follow-up HbA1c data were stratified according to having an average HbA1c during the first year of follow-up <6.0%, 6.0%-<6.5%, or ≥6.5% and their subsequent 5-year incidence rates of CVD compared according to sex, low-density lipoprotein cholesterol (LDL-C), and treatment arm.

Results: Overall, risk of CVD was significantly 2.4 times higher in individuals with HbA1c ≥6.5% versus <6.0%. A similar relation was noted in men and women (hazard ratio [HR], 2.1; p <0.01 and HR, 3.0; p <0.01, respectively) and was regardless of treatment arm (diet alone group: HR, 2.2; p <0.001; diet plus pravastatin group: HR, 1.8; p = 0.02). Spline curves showed a continuous risk increase according to HbA1c level in all subpopulations studied.

Conclusions: In hypercholesterolemic individuals the risk of CVD increases linearly with HbA1c level. This significant contribution by elevated HbA1c to increased CVD is independent of pravastatin therapy, and thus requires appropriate HbA1c management in addition to lipid reduction.

Keywords: Hemoglobin A1c (HbA1c), cardiovascular disease (CVD), hypercholesterolemia, HMG CoA reductase inhibitor, pravastatin, MEGA Study
patients with a specific disease background such as hypercholesterolemia.

This subanalysis evaluated the relation between HbA1c and CVD using data from the long-term, large-scale Management of Elevated Cholesterol in the Primary Prevention Group of Adult (MEGA) Study conducted in Japan in the late 1990s to mid-2000s [8,9].

**Methods**

The design, baseline characteristics, and major outcomes of the prospective, randomized, open-label, blinded endpoints MEGA Study have been described previously [8,9]. Briefly, 7832 patients (2476 men and 5356 postmenopausal women) aged 40-70 years with mild-to-moderate hypercholesterolemia (total cholesterol [TC] level, 5.7-6.0 mmol/L) without CVD were randomly allocated to either the diet group or diet plus pravastatin (10-20 mg/day, the approved dose in Japan) group for a mean follow-up period of 5.3 years. Patients in both arms were counseled to follow the National Cholesterol Education Program (NCEP) Step I diet [10] throughout the study period. Pravastatin was initiated at 10 mg/day; however, if the TC level did not decrease to ≤5.7 mmol/L the dosage could be uptitrated to 20 mg/day, in compliance with Japanese dosing instructions. Patients whose TC remained >5.7 mmol/L, even after enhancement of assigned treatment, could be switched to other aggressive treatments including other statins. Concomitant treatment for complications was not restricted in both groups. The primary composite endpoint was first occurrence of coronary heart disease (CHD) comprising fatal and nonfatal myocardial infarction, angina pectoris, cardiac/sudden death, and coronary revascularization procedure. Secondary endpoints included all strokes, smoking status.

Results

Baseline clinical and demographics characteristics of the 4002 patients included in this analysis are summarized in Table 1. Two thirds of the patients (66%) were women; men were about 4 years younger than women and had a slightly higher BMI. Confirmed diabetes, and consequently average FPG and HbA1c, were higher in men, whereas confirmed hypertension was higher in women. LDL-C and HDL-C were somewhat lower, and HDL-C higher, in men than women.

The incidence of cardiovascular events in men and women was compared among the three categories of HbA1c levels in Table 2. Comparing the ≥6.5% versus <6.0% HbA1c group overall, CHD was significantly higher (HR, 3.1; p <0.01), and also in men (HR, 2.3; p <0.01) and women (HR, 4.9; p <0.01). Moreover, CVD was significantly increased (HR, 2.4; p <0.01), and in men (HR, 2.1; p <0.01) and women (HR, 2.9; p <0.01). As the HbA1c level increased, the incidence of CHD and CVD increased. Whereas, stroke incidence
was slightly higher in the HbA1c ≥6.5% group for the total population and in men and in women, although it did not reach statistical significance. In men, but not women, there was a significant trend for increased mortality as HbA1c levels increased.

Comparing patients whose HbA1c was ≥6.5% versus <6.0% by treatment arm revealed that CVD was significantly increased in the diet alone group (HR, 2.2, p <0.001) and similarly in diet plus pravastatin group (HR, 1.33). In this analysis, although the small number of events, we nonetheless observed a proportional risk reduction in each HbA1c category in the diet plus pravastatin group compared with diet alone group (in patients with HbA1c ≥6.0%-7.0%, <6.0%; thereafter the risk increased more gently (Figure 1) in patients with HbA1c ≥6.5% versus <6.5%.

The spline curves for CVD exhibited a linear increase in risk as HbA1c increased until approximately HbA1c ≥6.6%-6.7% and risk of CVD in Japanese patients ≥6.5% was 16.5 and 5.7 per 1000 patient-years, respectively [19]. Although the results are broadly consistent when using fasting glucose and HbA1c as markers for glucose abnormalities to determine the HRs, 5% of the patients with HbA1c ≥6.1% actually had normal fasting glucose levels (data not shown). Since the HbA1c level is affected by post-prandial glucose excursions more than the fasting glucose level [20], evaluating HbA1c in addition to fasting glucose is useful to identify people at high risk.

In our previous report, we stated that the incidence of CVD in patients with or without abnormal fasting glucose was 16.5 and 5.7 per 1000 patient-years, respectively. In the present study, the incidences of CVD in patients with HbA1c ≥6.1% and <6.1% were 16.9 and 6.1 per 1000 patient-years, respectively [19]. Although the results are broadly consistent when using fasting glucose and HbA1c as markers for glucose abnormalities to determine the HRs, 5% of the patients with HbA1c ≥6.1% actually had normal fasting glucose levels (data not shown). Since the HbA1c level is affected by post-prandial glucose excursions more than the fasting glucose level [20], evaluating HbA1c in addition to fasting glucose is useful to identify people at high risk.

Statins can reduce CVD onset in the settings of primary and secondary prevention [21-25]. Benefits of statin therapy have been reported in patients with diabetes [9,19,26] and confirmed in a large-scale meta-analysis that implied that statins reduce CVD risk in diabetic and nondiabetic populations [27]. In this study, although statistical significance was not reached probably due to the small number of events, we nonetheless observed a proportional risk reduction in each HbA1c category in the diet plus pravastatin group compared with diet alone group (in patients with HbA1c <6.0%, 6.0%-<6.5%, and ≥6.5%, HR = 0.64, 0.72, and 0.81, respectively).

Discussion

We found a significant relation between having an HbA1c level ≥6.5% and risk of CVD in Japanese patients with hypercholesterolemia. This analysis compared three categories of HbA1c levels as measured according to new International Expert Committee criteria. Significant relations between increased HbA1c level and CHD and CVD were observed in men and women. A continuous increase in CVD risk as HbA1c level rose was confirmed by the spline method, which indicated that there is no threshold between CVD risk and HbA1c level. Recent reports have demonstrated that including HbA1c level in the assessment model could help to identify subjects at high risk, and that the predictability was improved by also including lipid levels [14]. Therefore, evaluating the relationship between HbA1c and CVD in patients with hypercholesterolemia is important to identify patients in a high-risk population.

The incidence of microvascular disease is known to increase with higher HbA1c levels. For instance, diabetic retinopathy occurs at a high rate in persons with HbA1c >6.0%-7.0% [15]. The Kumamoto Study in Japan demonstrated that the risk of retinopathy and nephropathy starts to increase as HbA1c rises above 6.6%-6.7% (NGSP) [16]. Macrovascular disease also is affected by a high HbA1c. In the Framingham Heart Study, a 1% increase in HbA1c was associated with a 1.39-fold increased risk of CVD [17]. A graded association between HbA1c and carotid intima-media thickness was found in the Atherosclerosis Risk in Communities (ARIC) study [18]. The Suita Study [11] recently reported a significantly increased risk of CVD associated with high HbA1c. Although it appears clear from these epidemiologic data and interventional studies that increased HbA1c levels are associated with raised CVD risk, we believe that the present findings are the first such demonstration in the setting of hypercholesterolemia, which itself confers high risk for CVD. Our data indicate that the significant relation between CVD risk and HbA1c ≥6.5% observed in hypercholesterolemia is similar to that seen in the general population.

In our previous report, we stated that the incidence of CVD in patients with or without abnormal fasting glucose was 16.5 and 5.7 per 1000 patient-years, respectively. In the present study, the incidences of CVD in patients with HbA1c ≥6.1% and <6.1% were 16.9 and 6.1 per 1000 patient-years, respectively [19]. Although the results are broadly consistent when using fasting glucose and HbA1c as markers for glucose abnormalities to determine the HRs, 5% of the patients with HbA1c ≥6.1% actually had normal fasting glucose levels (data not shown). Since the HbA1c level is affected by post-prandial glucose excursions more than the fasting glucose level [20], evaluating HbA1c in addition to fasting glucose is useful to identify people at high risk.

Statins can reduce CVD onset in the settings of primary and secondary prevention [21-25]. Benefits of statin therapy have been reported in patients with diabetes [9,19,26] and confirmed in a large-scale meta-analysis that implied that statins reduce CVD risk in diabetic and nondiabetic populations [27]. In this study, although statistical significance was not reached probably due to the small number of events, we nonetheless observed a proportional risk reduction in each HbA1c category in the diet plus pravastatin group compared with diet alone group (in patients with HbA1c <6.0%, 6.0%-<6.5%, and ≥6.5%, HR = 0.64, 0.72, and 0.81, respectively).
Table 2 Incidence of CVD events in relation to HbA1c level

| % HbA1c | Men | Women | All |
|---------|-----|-------|-----|
|         | Events/pts, n (/1000 py) | HR (95%CI) | p-value | Trend-p | Events/pts, n (/1000 py) | HR (95%CI) | p-value | Trend-p | Events/pts, n (/1000 py) | HR (95%CI) | p-value | Trend-p |
| CHD     | <6.0 | 16/630 (5.6) | 1.0 | - | 9/1481 (1.3) | 1.0 | - | 25/2111 (2.6) | 1.0 | - |
|         | 6.0-<6.5 | 7/226 (7.1) | 1.2 | (0.5-2.9) | 0.73 | (0.4-1.3) | 2.1 | (0.7-6.0) | 0.16 | (0.02-0.8) | 13/645 (4.5) | 1.5 | (0.8-2.9) |
|         | ≥6.5 | 33/518 (14.7) | 2.3 | (1.3-4.2) | <0.01 | 24/728 (7.2) | 4.9 | (2.2-10.6) | <0.01 | 57/1246 (10.3) | 3.1 | (1.9-5.0) |
| Stroke (all) |         |         |       |     |         |       |     |         |       |         |     |
|         | <6.0 | 11/630 (3.9) | 1.0 | - | 13/1481 (1.9) | 1.0 | - | 24/2111 (2.5) | 1.0 | - |
|         | 6.0-<6.5 | 5/226 (5.0) | 1.1 | (0.4-3.3) | 0.82 | (0.3-1.1) | 1.0 | (0.3-3.1) | 0.63 | (0.1-2.2) | 9/645 (3.1) | 1.1 | (0.5-2.3) |
|         | ≥6.5 | 15/518 (6.5) | 1.5 | (0.7-3.2) | 0.33 | (0.3-1.1) | 1.8 | (0.8-3.9) | 0.13 | (0.06-0.3) | 29/1246 (5.1) | 1.7 | (1.0-2.9) |
| CVD     | <6.0 | 27/630 (9.6) | 1.0 | - | 26/1481 (3.9) | 1.0 | - | 53/2111 (2.5) | 1.0 | - |
|         | 6.0-<6.5 | 12/226 (12.2) | 1.2 | (0.6-2.3) | 0.69 | (0.3-1.1) | 1.2 | (0.6-2.5) | 0.64 | (0.3-1.3) | 22/645 (7.7) | 1.2 | (0.7-2.0) |
|         | ≥6.5 | 50/518 (22.9) | 2.1 | (1.3-3.4) | <0.01 | 42/728 (12.8) | 2.9 | (1.8-4.7) | <0.01 | 92/1246 (16.9) | 2.4 | (1.7-3.4) |
| Death (total) |         |         |       |     |         |       |     |         |       |         |     |
|         | <6.0 | 4/630 (1.4) | 1.0 | - | 16/1481 (2.3) | 1.0 | - | 20/2111 (2.1) | 1.0 | - |
|         | 6.0-<6.5 | 5/226 (4.9) | 3.4 | (0.9-12.9) | 0.07 | (0.3-1.1) | 2.2 | (1.0-4.9) | 0.05 | (0.02-0.2) | 15/645 (5.1) | 2.3 | (1.0-4.4) |
|         | ≥6.5 | 16/518 (6.7) | 4.1 | (1.3-12.5) | 0.01 | (0.3-1.1) | 1.2 | (0.5-2.6) | 0.68 | (0.1-2.2) | 26/1246 (4.5) | 1.9 | (1.0-3.4) |

HR, 95%CI estimated by Cox proportional model adjusted by sex, age, treatment arm, baseline LDL-C, baseline HDL-C, hypertension, chronic kidney disease (estimated glomerular filtration rate <60), and smoking status.

Figure 1 Relation between HbA1c and CVD according to treatment arms. P-values were calculated against <6.0% in each group by Cox proportional hazard model adjusted for sex, age, treatment arm, baseline LDL-C, baseline HDL-C, hypertension, chronic kidney disease (estimated glomerular filtration rate <60), and smoking. *p <0.05; **p <0.01.
National guidelines recommend the aggressive management of CVD in patients with type 2 diabetes and that multidisciplinary interventions that includes weight, lipid and blood pressure control are needed to minimize the CVD risk, in addition to glucose lowering[28]. Statins offer an important therapeutic option for the management of lipids, particularly in type 2 diabetes. However, the relation between HbA1c and CVD was unaltered suggesting that appropriate HbA1c management is required in addition to lipids reduction. There are some hypotheses for the mechanisms by which hydrophilic statins may attenuate the deterioration of abnormal glucose metabolism in diabetic patients [29]. However, the HbA1c level was not significantly different between the diet plus pravastatin group and the diet alone group throughout the study period, as we have previously reported [19]. It is possible that adherence to diet therapy was somewhat worse in the diet plus pravastatin group than in the diet alone group, which may or may not influence the HbA1c level. However, we do not think we should focus on the effects of pravastatin on HbA1c levels in this analysis because there was no difference in HbA1c levels between the two groups.

There are two important limitations to the present analysis. First, it was conducted in patients whose TC was 5.7–6.0 mmol/L, and extrapolating these results to patients with higher TC concentrations should be done with caution. On the other hand, our patients had a broad range of LDL-C levels (1.4–4.6 mmol/L). Thus it appears that our findings may be quite generalizable. Second, the small number of events in the MEGA Study may affect the accuracy of the spline method. Therefore the tail analysis of data for sex, LDL-C level, and treatment arm were exploratory, especially in sparse tail area. In addition, an earlier study showed that all-cause mortality was increased in people with low HbA1c levels (<4.0%) [30]. Although we cannot assess the relationship between low HbA1c and high mortality because few patients with low HbA1c levels were included in this analysis, we should take this into account in clinical practice.

In conclusion, our results suggest that the HbA1c level should be included in prediction models for CVD risk. Controlling HbA1c independently of lipid management is necessary to reduce the risk of CVD in diabetic patients with elevated HbA1c.

Acknowledgements and funding
The authors sincerely thank the MEGA Study Group for providing their data.
Financial support for this retrospective subanalysis was provided by Daiichi-Sankyo Co, Ltd.

Author details
1Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan. 2Diabetes Center, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. 3Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, 3-2-7 Miya-machi, Mito, Ibaraki, 310-0015, Japan. 4Department of Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan. 5Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.

Authors’ contributions
RN carried out interpreting the data and writing the manuscript; TN, HS and NT carried out interpreting the data and reviewing the manuscript; YO carried out analyzing and reviewing the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 1 March 2011 Accepted: 30 June 2011
Published: 30 June 2011
References

1. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Diabet Med 1998, 15:539-553.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003, 26:539-553.
3. Ceriello A, Colagiuri S: International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabetic Med 2008, 25:1151-1156.
4. International Expert Committee: International Expert Committee Report on the Role of the HbA1c Assay in the Diagnosis of Diabetes. Diabetes Care 2009, 32:1327-1334.
5. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Branclati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
6. Blake GJ, Pradhan AD, Manson JE, Williams GR, Buring JE, Ridker PM, Glynn RJ: Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 2004, 164:757-761.
7. Gao L, Matthews FE, Sargeant LA, Brayne C, MRC CFAS: An investigation of the population impact of variation in HbA1c levels in older people in England and Wales: from a population based multi-centre longitudinal study. BMC Public Health 2005, 5:31.
8. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study: Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004, 68:860-867.
9. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Gohshi Y: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1153-1163.
10. National Cholesterol Education Program: Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) Washington, DC: US Department of Health and Human Services; 1993.
11. Committee on Diabetes Mellitus Indices, Japan Society of Clinical Chemistry: Japanese guideline for reporting HbA1c results reported in IFCC units and IDS units. Rinsho Kagaku 2008, 37:393-409 (In Japanese).
12. Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Okayama A, Okamura T, New diagnosis criteria for diabetes with hemoglobin A1C and risks of macro-vascular complications in an urban Japanese cohort: the Suita Study. Diabetes Res Clin Pract 2010, 88:602-623.
13. Greenland S: Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995, 6:356-365.
14. Chien RL, Lin HJ, Lee BC, Hsu HC, Chen MF: Prediction model for high glycated hemoglobin concentration among ethnic Chinese in Taiwan. Cardiovasc Diabetol 2010, 9:39.
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
16. Okubo Y, Kishikawa H, Ikeda M, Miyata T, Isami S, Motoyoshi S, Kojima Y, Futuyoshi N, Shihchi M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
17. Singer E, Nathan J, Anderson SH, Wilson PW, Evans JC: Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992, 41:202-208.
18. Selvin E, Coreil J, Golden SH, Boland LL, Branclati FL, Staffes MW, Atherosclerosis Risk in Community Study: Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the Atherosclerosis Risk in Community Study. Diabetes Care 2003, 28:1963-1973.
19. Tajima N, Kurata H, Nakaya N, Mizuno K, Ohashi Y, Kusunoki T, Teramoto T, Uchiyama S, Nakamura H: Primary Prevention Group of Adult Japanese (MEGA) Study: Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008, 199:653-662.
20. Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003, 26:881-885.
21. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JJ, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
22. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
23. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
24. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, Mchnnes GT, Mehlsen J, Neminen M, O'Brien E, Österberg J, ASCOT Investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcome Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
25. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARIB) Trial. The Care Investigators. Circulation 1998, 98:2517-2519.
26. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomson MJ, MacKessie NM, Charlton-Merys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
27. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C, Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
28. KuruKulseysu LR, Sowers JR: Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol 2010, 9:45-58.
29. Kostapanos MS, Liams GL, Milionis HJ, Elisaf MS: Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010, 8:612-631.
30. Carson AP, Fox CS, McGuire OK, Levitan EB, Laclastra M, Mann DM, Muntner P: Low hemoglobin A1C and risk of all-cause mortality among US adults without diabetes. Circ Cardiovasc Qual Outcomes 2010, 3:661-667.

doi:10.1186/1475-2840-10-58
Cite this article as: Nishimura et al.: Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. Cardiovascular Diabetology 2011 10:58.